Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22440191 | 0.86 | QPCT (0.49) | QPCTGAACDC7DBF4 | |
| SCHEMBL22440192 | 0.86 | DHFR (0.51) | QPCTLMNADHFRTSHRCYP1A2 | |
| SCHEMBL22440204 | 0.85 | CDC7 (0.56) | KMT2ACDC7DBF4 | |
| SCHEMBL22440207 | 0.83 | MAPT (0.53) | QPCTRAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL22440199 | 0.80 | MAPT (0.40) | QPCTRAB9ANPC1MAPTKDM4E | |
| SCHEMBL21295263 | 0.80 | PIK3CA (0.38) | QPCTMAPTDHFRKDM4EALDH1A1 | |
| SCHEMBL21303627 | 0.79 | RAB9A (0.47) | QPCTRAB9ANPC1POLBLMNA | |
| SCHEMBL2539376 | 0.79 | QPCT (0.67) | QPCTRAB9ANPC1POLBLMNA | |
| SCHEMBL22440210 | 0.78 | LTA4H (0.52) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL22440202 | 0.78 | NPC1 (0.43) | NPC1LMNADHFRTSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-04-16 | — | — | US | disclosed |
| US-20200392174-A1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2020-12-17 | — | — | US | disclosed |
| EP-3589632-B1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung Ev (DE) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392174-A1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | GMPS, GLS, QPCT | QPCT 3/4885RAB9A 667/4885NPC1 3544/4885 |
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | GMPS, GLS, QPCT | QPCT 3/4885RAB9A 660/4885NPC1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.